Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 1999

View Archived Issues

Proteasome inhibitor PS-519 demonstrates cardioprotective activity in preclinical model

News from FASEB: RC-522 provides cardioprotection without prodysrhythmic effects

Pentose and Cangene enter licensing agreement

Pharmacokinetics of Prandin shown to be similar in young adults and elderly

CoCensys initiates study with ganaxolone in patients with catamenial seizures

Cantab in-licenses Novasomes adjuvant for use in TA-CIN vaccine; clinical testing in sight

HDL-increasing compounds claimed by AHP for cardiovascular disease, dyslipoproteinemia

BASF claims series with mixed ETA/ETB-antagonist properties

Sugen sets up European affiliate and signs first major European partnership agreement

Novel antiviral agent active against HIV-1 and other viruses developed in Russia

Bristol-Myers Squibb signs formulation development agreement with Scotia

Follow-up results of phase III study support long-term efficacy of mitoxantrone in MS

Delayed administration of conantokin-G does not impair therapeutic efficacy in stroke model

Differentiation-inducing 5-FU prodrug developed at Spanish university

Improved antigen response to conjugate vaccine in mature vs. neonatal mice

New PRIMATIZED anti-CD80 antibodies engineered at Idec

Boehringer Ingelheim announces German launch of angiotensin II blocker

Results of first federally funded study of fetal cell therapy presented at AAN meeting

Selective ETB antagonist A-192621 used to explore role of ETB in blood pressure regulation

Donor bone marrow: an alternative to immunosuppressive drugs in transplantation?

Selective 5-HT1A ligands described by ADIR in recent patent

SS Pharm. presents new AGE inhibitors for use in diabetic complications

HMR seeks approval for long-acting insulin in U.S. and Europe

Coumarin derivatives with antiviral activity against HIV from Pliva

Lilly develops new antioxidants with particular utility as neuroprotectants

Agents with affinity for dopamine and 5-HT1A receptors in development at Duphar

New pyridinone-based analgesic/antiinflammatory agents designed by Turkish team

SmithKline Beecham enters copromotion agreement with Bristol-Myers Squibb for Avandia

Synthelabo: Annual Report 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.